Aclarion announced the launch of the multi-center CLUE Trial to quantify how often a surgeon changes their original treatment plan once they have access to proprietary Nociscan data. Data from CLUE will provide tremendous insight into the real-world value of adding the Nociscan decision support tool to existing diagnostic evaluation methods for the treatment of chronic low back pain. Aclarion announced the launch of CLARITY earlier this year to definitively demonstrate better surgical outcomes when Nociscan data is included in the surgical decisioning process. CLARITY is a gold standard, multicenter, prospective randomized trial. CLUE is aimed at providing near term insights into the probability of success of CLARITY by quantifying how often Nociscan data results in a surgeon changing their original treatment decision.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACON:
- Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
- Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
- Aclarion announces first commercial agreement in Michigan
- Aclarion Announces First Commercial Agreement in Michigan
- Aclarion announces their third payer coverage of Nociscan by Vitality in London